Literature DB >> 22689861

E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.

Kamil Wolyniec1, Jake Shortt, Elisa de Stanchina, Yaara Levav-Cohen, Osnat Alsheich-Bartok, Igal Louria-Hayon, Vincent Corneille, Beena Kumar, Simone J Woods, Stephen Opat, Ricky W Johnstone, Clare L Scott, David Segal, Pier Paolo Pandolfi, Stephen Fox, Andreas Strasser, Yong-Hui Jiang, Scott W Lowe, Sue Haupt, Ygal Haupt.   

Abstract

Neoplastic transformation requires the elimination of key tumor suppressors, which may result from E3 ligase-mediated proteasomal degradation. We previously demonstrated a key role for the E3 ubiquitin ligase E6AP in the regulation of promyelocytic leukemia protein (PML) stability and formation of PML nuclear bodies. Here, we report the involvement of the E6AP-PML axis in B-cell lymphoma development. A partial loss of E6AP attenuated Myc-induced B-cell lymphomagenesis. This tumor suppressive action was achieved by the induction of cellular senescence. B-cell lymphomas deficient for E6AP expressed elevated levels of PML and PML-nuclear bodies with a concomitant increase in markers of cellular senescence, including p21, H3K9me3, and p16. Consistently, PML deficiency accelerated the rate of Myc-induced B-cell lymphomagenesis. Importantly, E6AP expression was elevated in ∼ 60% of human Burkitt lymphomas, and down-regulation of E6AP in B-lymphoma cells restored PML expression with a concurrent induction of cellular senescence in these cells. Our findings demonstrate that E6AP-mediated down-regulation of PML-induced senescence is essential for B-cell lymphoma progression. This provides a molecular explanation for the down-regulation of PML observed in non-Hodgkin lymphomas, thereby suggesting a novel therapeutic approach for restoration of tumor suppression in B-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689861      PMCID: PMC3709628          DOI: 10.1182/blood-2011-10-387647

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

1.  PML is induced by oncogenic ras and promotes premature senescence.

Authors:  G Ferbeyre; E de Stanchina; E Querido; N Baptiste; C Prives; S W Lowe
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

2.  The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice.

Authors:  W Y Langdon; A W Harris; S Cory; J M Adams
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

3.  Role of PML in cell growth and the retinoic acid pathway.

Authors:  Z G Wang; L Delva; M Gaboli; R Rivi; M Giorgio; C Cordon-Cardo; F Grosveld; P P Pandolfi
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

4.  Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence.

Authors:  Maurice Reimann; Soyoung Lee; Christoph Loddenkemper; Jan R Dörr; Vedrana Tabor; Peter Aichele; Harald Stein; Bernd Dörken; Thomas Jenuwein; Clemens A Schmitt
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

5.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

6.  Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim.

Authors:  Lina Happo; Mark S Cragg; Belinda Phipson; Jon M Haga; Elisa S Jansen; Marco J Herold; Grant Dewson; Ewa M Michalak; Cassandra J Vandenberg; Gordon K Smyth; Andreas Strasser; Suzanne Cory; Clare L Scott
Journal:  Blood       Date:  2010-09-09       Impact factor: 22.113

Review 7.  Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Authors:  B C Potts; M X Albitar; K C Anderson; S Baritaki; C Berkers; B Bonavida; J Chandra; D Chauhan; J C Cusack; W Fenical; I M Ghobrial; M Groll; P R Jensen; K S Lam; G K Lloyd; W McBride; D J McConkey; C P Miller; S T C Neuteboom; Y Oki; H Ovaa; F Pajonk; P G Richardson; A M Roccaro; C M Sloss; M A Spear; E Valashi; A Younes; M A Palladino
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

8.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

Authors:  F S Leach; T Tokino; P Meltzer; M Burrell; J D Oliner; S Smith; D E Hill; D Sidransky; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

9.  Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence.

Authors:  Masashi Narita; Sabrina Nũnez; Edith Heard; Masako Narita; Athena W Lin; Stephen A Hearn; David L Spector; Gregory J Hannon; Scott W Lowe
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

10.  The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells.

Authors:  A W Harris; C A Pinkert; M Crawford; W Y Langdon; R L Brinster; J M Adams
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  29 in total

1.  Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.

Authors:  Ya-Ting Wang; Jocelyn Chen; Chou-Wei Chang; Jayu Jen; Tzu-Yu Huang; Chun-Ming Chen; Roger Shen; Suh-Yuen Liang; I-Cheng Cheng; Shuenn-Chen Yang; Wu-Wei Lai; Kuang-Hung Cheng; Tao-Shih Hsieh; Ming-Zong Lai; Hung-Chi Cheng; Yi-Ching Wang; Ruey-Hwa Chen
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

Review 2.  The role of E3 ubiquitin ligase HECTD3 in cancer and beyond.

Authors:  Qiuyun Jiang; Fubing Li; Zhuo Cheng; Yanjie Kong; Ceshi Chen
Journal:  Cell Mol Life Sci       Date:  2019-10-21       Impact factor: 9.261

3.  LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.

Authors:  Gretchen L Bentz; Charles Randall Moss; Christopher B Whitehurst; Cary A Moody; Joseph S Pagano
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

4.  Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells.

Authors:  Twishi Gulati; Cheng Huang; Franco Caramia; Dinesh Raghu; Piotr J Paul; Robert J A Goode; Simon P Keam; Scott G Williams; Sue Haupt; Oded Kleifeld; Ralf B Schittenhelm; Cristina Gamell; Ygal Haupt
Journal:  Mol Cell Proteomics       Date:  2018-02-20       Impact factor: 5.911

5.  Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.

Authors:  P J Paul; D Raghu; A-L Chan; T Gulati; L Lambeth; E Takano; M J Herold; J Hagekyriakou; R L Vessella; C Fedele; M Shackleton; E D Williams; S Fox; S Williams; S Haupt; C Gamell; Y Haupt
Journal:  Oncogene       Date:  2016-09-19       Impact factor: 9.867

6.  KLHL39 suppresses colon cancer metastasis by blocking KLHL20-mediated PML and DAPK ubiquitination.

Authors:  H Y Chen; J Y Hu; T H Chen; Y C Lin; X Liu; M Y Lin; Y D Lang; Y Yen; R H Chen
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

7.  Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.

Authors:  Hai Vu Nguyen; Cassandra J Vandenberg; Ashley P Ng; Mikara R Robati; Natasha S Anstee; Joel Rimes; Edwin D Hawkins; Suzanne Cory
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113

Review 8.  HECT E3 ubiquitin ligases - emerging insights into their biological roles and disease relevance.

Authors:  Yaya Wang; Diana Argiles-Castillo; Emma I Kane; Anning Zhou; Donald E Spratt
Journal:  J Cell Sci       Date:  2020-04-07       Impact factor: 5.285

Review 9.  The role of PML ubiquitination in human malignancies.

Authors:  Ruey-Hwa Chen; Yu-Ru Lee; Wei-Chien Yuan
Journal:  J Biomed Sci       Date:  2012-08-30       Impact factor: 8.410

10.  Identification of RNF168 as a PML nuclear body regulator.

Authors:  Kathy Shire; Andrew I Wong; Michael H Tatham; Oliver F Anderson; David Ripsman; Stephanie Gulstene; Jason Moffat; Ronald T Hay; Lori Frappier
Journal:  J Cell Sci       Date:  2015-12-16       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.